Akorn (AKRX) Getting Somewhat Favorable News Coverage, Accern Reports
Press coverage about Akorn (NASDAQ:AKRX) has trended somewhat positive on Saturday, Accern reports. Accern identifies negative and positive media coverage by analyzing more than twenty million news and blog sources in real time. Accern ranks coverage of companies on a scale of negative one to positive one, with scores nearest to one being the most favorable. Akorn earned a media sentiment score of 0.17 on Accern’s scale. Accern also assigned press coverage about the company an impact score of 46.0139917174689 out of 100, meaning that recent media coverage is somewhat unlikely to have an impact on the company’s share price in the next several days.
These are some of the media headlines that may have effected Accern Sentiment Analysis’s analysis:
- IHS Markit Score downgrades Akorn Inc to 21 out of 100, ranking positively in only one out of three available IHS Markit categories. (finance.yahoo.com)
- Akorn, Inc. (NASDAQ:AKRX) Receives Average Recommendation of “Hold” from Analysts (americanbankingnews.com)
- HollyFrontier Corporation (HFC) Shares Sold by AQR Capital Management LLC (famososartistas.com)
- Police release CCTV of 83-year-old dog walker stabbed to death (wisdomsave.com)
- Municipal Employees Retirement System of Michigan Decreases Stake in Akorn, Inc. (AKRX) (ismboard.com)
AKRX has been the topic of a number of research reports. Jefferies Group LLC downgraded shares of Akorn from a “buy” rating to a “hold” rating and raised their price objective for the stock from $24.00 to $34.00 in a report on Tuesday, April 25th. BidaskClub raised shares of Akorn from a “hold” rating to a “buy” rating in a report on Saturday, June 24th. TheStreet raised shares of Akorn from a “c+” rating to a “b-” rating in a report on Thursday, April 20th. Piper Jaffray Companies downgraded shares of Akorn from an “overweight” rating to a “neutral” rating and raised their price objective for the stock from $29.00 to $34.00 in a report on Tuesday, April 25th. Finally, Royal Bank Of Canada reissued a “hold” rating and issued a $34.00 price objective on shares of Akorn in a report on Tuesday, April 25th. Four equities research analysts have rated the stock with a sell rating, nine have assigned a hold rating and one has issued a buy rating to the stock. Akorn currently has an average rating of “Hold” and a consensus price target of $28.56.
Shares of Akorn (AKRX) opened at 33.31 on Friday. The firm’s 50-day moving average is $33.54 and its 200-day moving average is $29.05. The company has a market cap of $4.16 billion, a PE ratio of 33.65 and a beta of 1.36. Akorn has a 1-year low of $17.61 and a 1-year high of $34.00.
In other Akorn news, Director Brian Tambi sold 5,165 shares of the company’s stock in a transaction that occurred on Friday, August 4th. The stock was sold at an average price of $33.37, for a total value of $172,356.05. The transaction was disclosed in a document filed with the SEC, which is accessible through this link. Also, COO Bruce Kutinsky sold 40,000 shares of the company’s stock in a transaction that occurred on Thursday, August 3rd. The stock was sold at an average price of $33.46, for a total value of $1,338,400.00. Following the completion of the sale, the chief operating officer now owns 317,480 shares in the company, valued at approximately $10,622,880.80. The disclosure for this sale can be found here. Corporate insiders own 28.20% of the company’s stock.
Akorn Company Profile
Akorn Inc (Akorn), together with its subsidiaries, is a specialty generic pharmaceutical company that develops, manufactures and markets generic and branded prescription pharmaceuticals, as well as private-label over-the-counter (OTC) consumer health products and animal health pharmaceuticals. The Company operates through two segments: Prescription Pharmaceuticals and the Consumer Health.
Receive News & Ratings for Akorn Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Akorn Inc. and related companies with MarketBeat.com's FREE daily email newsletter.